Teva Pharmaceuticals USA is recalling 1,373 cartons of Clonazepam Orally Disintegrating Tablets USP (2 mg) because the medication failed routine stability testing for water content. This prescription drug, used to treat certain seizure and anxiety disorders, may not meet quality standards throughout its shelf life due to this moisture issue. Consumers who have the affected 60-count cartons from the specific lot should be aware of this quality defect and take appropriate action to ensure their medication remains effective.
The tablets failed testing for water content, which can compromise the stability and chemical integrity of the medication over time. This may result in the drug losing its potency or failing to perform as expected before its expiration date.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.